CompletedPhase 3NCT02026063

Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms

Studying Carcinoid syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Lexicon Pharmaceuticals
Principal Investigator
Pablo Lapuerta, MD
Lexicon Pharmaceuticals, Inc.
Intervention
Telotristat etiprate(drug)
Enrollment
124 enrolled
Eligibility
18 years · All sexes
Timeline
20142018

Study locations (30)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02026063 on ClinicalTrials.gov

Other trials for Carcinoid syndrome

Additional recruiting or active studies for the same condition.

See all trials for Carcinoid syndrome

← Back to all trials